Published in Cancer Weekly, October 15th, 2002
Submitted under the trade name Gamunex, Bayer BP's new IGIV-C product introduces a breakthrough purification process, Caprylate/Chromatography, designed to establish new standards in product purity and supply reliability. Gamunex is the first newly developed IgIV product to be submitted to the U.S. Food and Drug Administration (FDA) in over a decade and its production process differs significantly from traditional IGIV manufacturing processes that are based on methods first...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.